Clinical Efficacy of Metoprolol Succinate Extended-Release Tablets in the Treatment of Post-Myocardial Infarction Ventricular Arrhythmias

Objective: To investigate the clinical efficacy of metoprolol succinate extended-release tablets in the treatment of post-myocardial infarction ventricular arrhythmias. Methods: The clinical data of 84 patients with post-myocardial infarction ventricular arrhythmia included in the study were collected and they were divided into Groups A and B with 42 cases each using the randomization method. Group A was treated with oral glucosamine hydrochloride, while Group B was administered oral metoprolol succinate extended-release tablets. Combined indicators were used to evaluate the improvement of clinical indicators, therapeutic effects, and the incidence of adverse reactions in the two groups. Results: The baseline data of the two groups of patients were not statistically significant (Pall > 0.05); after treatment, the QT dispersion, corrected QT dispersion, and heart rate of Group B were lower than that of Group A (Pall = 0.000 < 0.001); the total clinical effectiveness of Group B was 95.24%, which was significantly higher than 80.95% in Group A (χ2 = 4.087, P = 0.043 < 0.05); the total incidence of adverse reactions in Group B was 4.76%, which was significantly lower than 19.04% in Group A (χ2 = 4.087, P = 0.043 < 0.05). Conclusion: In the treatment of post-myocardial infarction ventricular arrhythmia, the use of metoprolol succinate extended-release tablets can effectively correct the QT dispersion of patients, improve their heart rate, increase clinical effectiveness, and reduce the incidence of adverse reactions.